Cerity Partners LLC Sells 11,676 Shares of DaVita Inc. (NYSE:DVA)

Cerity Partners LLC trimmed its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 59.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,968 shares of the company's stock after selling 11,676 shares during the quarter. Cerity Partners LLC's holdings in DaVita were worth $1,270,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. MML Investors Services LLC lifted its holdings in DaVita by 1.3% during the 3rd quarter. MML Investors Services LLC now owns 5,300 shares of the company's stock worth $869,000 after buying an additional 68 shares in the last quarter. Te Ahumairangi Investment Management Ltd lifted its stake in shares of DaVita by 1.0% during the third quarter. Te Ahumairangi Investment Management Ltd now owns 48,137 shares of the company's stock valued at $7,846,000 after acquiring an additional 500 shares during the period. Tidal Investments LLC boosted its holdings in DaVita by 45.2% in the third quarter. Tidal Investments LLC now owns 5,688 shares of the company's stock valued at $932,000 after acquiring an additional 1,771 shares during the last quarter. Franklin Resources Inc. increased its position in DaVita by 134.6% in the third quarter. Franklin Resources Inc. now owns 54,901 shares of the company's stock worth $8,885,000 after purchasing an additional 31,502 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in DaVita by 17.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock worth $99,846,000 after purchasing an additional 92,014 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company's stock.

DaVita Stock Up 2.7 %

Shares of NYSE:DVA traded up $3.69 during mid-day trading on Wednesday, reaching $138.66. 113,129 shares of the stock were exchanged, compared to its average volume of 899,269. The stock's 50 day simple moving average is $147.51 and its 200-day simple moving average is $155.64. DaVita Inc. has a one year low of $130.96 and a one year high of $179.60. The company has a market cap of $11.09 billion, a P/E ratio of 12.91, a P/E/G ratio of 1.07 and a beta of 1.04. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. As a group, equities research analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

Analyst Upgrades and Downgrades

DVA has been the subject of several analyst reports. Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a research report on Friday, February 21st. Cowen reaffirmed a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Barclays increased their price target on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Tuesday, February 18th. Finally, StockNews.com upgraded shares of DaVita from a "hold" rating to a "buy" rating in a report on Thursday, April 10th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat, DaVita presently has an average rating of "Hold" and a consensus target price of $166.33.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.